Drug Type Synthetic peptide |
Synonyms 司美格鲁肽注射液, HY310 |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Obesity | Phase 3 | China | 02 Sep 2024 | |
Diabetes Mellitus, Type 2 | Phase 3 | China | 24 Aug 2024 |
Not Applicable | 20 | mzfugguhyo(izzkzvrfis) = npnoaiovkt apkdqdvdbg (ffimcvrskn ) View more | Positive | 01 Nov 2022 | |||
Placebo | mzfugguhyo(izzkzvrfis) = jzydpvukzl apkdqdvdbg (ffimcvrskn ) View more |